Research Advances Hold Promise for Multiple Myeloma Treatment - Insight
Multiple myeloma is one of the most compelling examples of a cancer in which research has markedly improved the length and quality of patients’ lives in the last decade. A malignancy of certain white blood cells in the bone marrow known as plasma cells, myeloma is still considered incurable, but treatment advances have significantly improved survival. Not long ago, patients with myeloma lived a median time of two to three years after diagnosis. Today, median survival is seven to 10 years, although this can be unpredictable, with some patients living longer and others surviving for significantly shorter time periods.